Sayed Taha Email & Phone Number

Riyadh Province, Saudi Arabia

Riyadh, Saudi Arabia

Enlisting and promoting products of (EVER PHARMA, Versalya, Zambon, Actavis and Labatec. Launching Blum D , Premaban, Imipenem and Parafusive.Conducting Anasthesia ,ICU,Gyna,Neuro and Rare diseases KOLs (cancer Colone, premature birth and parkinsonism)Analyzing market to identify new opportunities.Led and managed administrative staff to maintain smooth daily operations. Prioritised and assigned tasks for strategic and optimised distribution of workloads.Mediated team decision-making and problem-solving for peaceful resolutions and decision-making.Professionally handled difficult customer complaints and objections to maintain first-class customer service standards.Achieved 130% in 2023 with growth 50% vs 2022Spearheaded the enlistment and promotion of products from EVER PHARMA, Versalya, Zambon, Actavis, and Labatec, achieving a 130% sales increase in 2023.Captured 60% of the Dexmedetomidine market and 80% of the Atosiban market with growth 190% Implemented protocols for premature labor with cooperation of medical department within top customers Delegated tasks to make best use of individuals' skills.

Riyadh, Saudi Arabia

Developed new products by team and solidifying sales partnerships (CNS, CVS, Neuro, Endocrinology and Dialysis)Developed and launched 38 new products including generics and life-saving medications.Captured 60% of the KSA sales with the highest growth and achievementAchieved 60% of potent P2Y12 inhibitors in Dallah & SMC hospitalsManaged team of 8 fresh candidates 2 of them was best performers by end 2022 Applied critical thinking to analyse problems, evaluate solutions and select best decisions. Oversaw daily operations to achieve high productivity levels.

Abha, 'Asir, Saudi Arabia

SANOFI - Southern region, KSALaunched and promoted CHC and hematology nephrology products, achieved best performer status across KSA in 2017,2019 and 2020.Increased market share for LANZOR from 10% in 2013 to 60% in 2016Increased MS% of Clexane from 61% in 2017 to 91% by end of 2019Implemented Renvila (sevelamer) in private hospitals for first time in southern region SANOFI golden runner 2015

Upper Egypt

Exforge and Exforge HCT launch